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Background: Inflammatory Bowel Disease (IBD) is a collective term that refers to 
chronic inflammatory diseases involving the gastrointestinal (GI) tract.  The most 
common forms of IBD include Crohn’s Disease (CD) and ulcerative colitis (UC).  
 
Goals: The goal of this study is to compare baseline and one-year follow-up measures of 
anxiety, depression, and quality of life in children with newly diagnosed IBD. A 
secondary goal of this study is to determine if there are parallel changes in the 
psychologic parameters in the parents of these children over a similar one-year interval.   
 
Methods: This prospective cohort study was conducted in the Center for Inflammatory 
Bowel Diseases at Boston Children’s Hospital (BCH). The parents and children with 
newly diagnosed IBD completed validated questionnaires about their disease at baseline 
(within six months of their diagnosis) and then again 12-18 months later. 
 
vi		
Results: Baseline data were collected from 75 patients with IBD, and 15 of these 
patient/parent dyads have completed follow-up questionnaires. The incidence of anxiety 
and depression trended downwards after the first year, and overall quality of life trended 
upwards, indicating an improvement in a global state of adjustment. Measures of anxiety 
and depression, as well as the reported frequency and difficulty of adverse events, all 
decreased in parental responses after the first year.  
 
Conclusion: While a larger sample size is necessary to better assess changes in 
psychometrics over time, existing data suggests that parents manifest the most significant 
change in anxiety and depression over the course of the first year from diagnosis.  
Children appear to be less anxious and depressed at baseline. Further enrollment and data 
collection will permit a more definitive assessment of the relationship between patient 
and parent coping strategies.  Ideally, the results of this ongoing study will determine if 
impaired parental coping lowers a patient’s quality of life, contributes to higher 
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Inflammatory Bowel Disease: 
	 Inflammatory bowel disease (IBD) is a collection of chronic inflammatory 
disorders affecting the lining of the gastrointestinal tract.  While the pathogenesis of IBD 
has not been fully revealed, existing data have implicated both environmental influences 
and hereditary factors.  Presenting clinical symptoms include fatigue, abdominal pain, 
bloody stools, diarrhea, anorexia, and weight loss (Perler et al. 2019).  The two main 
types of IBD are Crohn’s disease and ulcerative colitis.  While the clinical symptoms of 
both disorders overlap, their pathogenesis can differ considerably. The inflammation 
observed in patients with CD can occur in any portion of their GI tract. 
In contrast, the inflammation observed in patients with UC patients is limited to 
the large intestine and almost always involves the mucosa lining the rectum. Patients with 
CD often present with more indolent symptoms, including fatigue and anorexia, while 
patients with UC typically present with bloody diarrhea and frequent bowel movements 
 
Diagnostics for IBD: 
 A number of clinical, radiologic, and histologic features can help clinicians to 
accurately diagnose a patient with IBD, as seen in Table 1 (North American Society, 
2007).  As such, patients presenting with symptoms consistent with IBD undergo upper 
endoscopic and colonoscopic evaluations, as well as a battery of serologic testing and 
radiologic studies, in an effort to distinguish between a diagnosis of CD or UC (Bernstein 
et al. 2009).  Previous studies have demonstrated increased inflammatory markers 
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(including interleukins and cytokines) and immunocompetent cells in the mucosa of 
patients with active IBD (Belarif et al. 2019). Assessment of fecal proteins, including 
calprotectin and lactoferrin, can also help to identify patients with active/ongoing 
intestinal inflammation (Bernstein et al. 2009). 
Radiologic studies are relied upon to identify the location and severity of 
intestinal inflammation. Magnetic resonance imaging (MRI) and computer-assisted 
tomography (CT) provide clinicians with the ability to assess portions of the small 
intestine not typically accessible using standard endoscopic techniques.  (Rosen, Dhawan, 
& Saeed, 2015).  Each study presents its advantages and limitations.  MRI studies 
provide superb soft tissue imaging data.  However, MRI studies take much longer, are 
generally less available, and may necessitate sedation in young children.  In contrast, 
while CT imaging is more available and much faster to complete, the associated ionizing 
radiation is a significant issue, particularly if repeated studies are needed.  For these 
reasons, endoscopic evaluation is considered the gold-standard in diagnosing and 
assessing disease activity in patients with IBD (Griffiths and Turner, 2009). 
  
Pediatric Inflammatory Bowel Disease: 
 Patients presenting with IBD as children often experience a more severe disease 
course than patients diagnosed after the third decade of life.  Overall, about 20% of 
patients with IBD will be diagnosed before age 20 (Rosen, Dhawan, and Saeed, 2015). 
While the presentation and diagnosis of IBD can be very similar in children and adults, 
there are several significant differences that clinicians must take into account. More 
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specifically, unlike adults, children diagnosed with CD or UC are vulnerable to 
experiencing delayed growth and development due to ongoing inflammation, anorexia, or 
impaired absorption of necessary nutrients. As such, clinicians caring for children with 
IBD must carefully monitor changes in height, weight, and BMI (Higuchi and Bousvaros, 
2017). Children diagnosed with ulcerative colitis are at an increased risk for colectomy 
(Krishna et al. 2019).  
The morbidities associated with managing a chronic illness, in addition to the risk 
of down-stream complications including short-stature or the need for surgical resection 
(patients with CD) or colectomy (patients with UC), can affect the psychological well-
being of children with IBD.  Due to these concerns, physicians must ensure that patients 
and their families have the supports required to meet the myriad medical and 
psychosocial complications. Therefore, the clinical approach to therapy is fundamentally 
different in children and adults with CD or UC.  
 
Therapies for Inflammatory Bowel Disease: 
At present, there are many therapies available to treat patients with IBD. Initially, 
most patients were treated with corticosteroids and sulfasalazine.  However, an improved 
understanding of the pathogenesis of UC and CD has resulted in the development of 
many more effective therapies.  There is no cure for IBD.  As such, the main goal of 
therapy is to improve the patient’s quality of life, reduce mucosal inflammation in the GI 
tract, and prevent the development of long-term complications. Anti-inflammatory drugs, 
including corticosteroids and 5-aminosalicylate derivatives, can reduce the production 
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and release of cytokines and thereby help to dampen the inflammatory response. Other 
conventional therapies include the immunomodulators methotrexate, 6-mercaptopurine, 
and azathioprine (Damiao et al. 2019).  
Corticosteroids are often employed to patients with IBD to help bring patients 
with active symptoms of IBD into clinical remission. However, corticosteroids are not 
suitable maintenance medications due to their long-term side effects, including acne, 
weight gain, and moon facies (Sauer and Kugathasan, 2010). Some physicians may 
recommend that a patient receive exclusive enteral nutrition (EEN). This strategy entails 
restricting 100% of a patient’s caloric delivery to polymeric enteral formulations (such as 
Ensure® or Pediasure®), and patients have no solid foods.  This approach can be very 
successful in healing inflammation in the GI tract while still providing adequate nutrition 
to the patient. Since children with IBD often have growth retardation and delayed puberty 
due to malnutrition, this is an ideal option over steroids because it avoids the side-effects 
but still promotes normal growth. (Sauer and Kugathasan, 2010) When patients present 
with disease that proved refractory to medical therapy or those that have developed 
penetrating or obstructive complications, surgery may become necessary (Sauer and 
Kugathasan, 2010). In children, physicians rely on validated metrics, including the 
Pediatric Crohn Disease Activity Index (PCDAI) and the Pediatric Ulcerative Colitis 
Activity Index (PUCAI), to assess disease severity and to choose the appropriate 





Psychosocial Effects of IBD: 
Along with the apparent physical effects of IBD, there are many ways in which 
IBD can impact independently on psychosocial well-being (Chao et al. 2019).  A child 
with a chronic disease puts an added level of stress on a family. Children unable to cope 
with their diagnosis, particularly in the context of parents unable or unwilling to meet the 
challenge, are at increased risk for a worse clinical outcome.  This study, therefore, will 
assess the coping mechanisms and psychological stresses of children who have recently 
been diagnosed with IBD. In parallel, we will be collecting information about the impact 
of the parental reaction on the child’s disease state and mental health. 
Patients who are diagnosed with IBD at a younger age may have a more difficult 
time coping than adults.  Symptoms associated with active IBD, including diarrhea, 
passing gas, delayed puberty, and the side effects of some medications, can be especially 
tricky to manage in the adolescent milieu.   These often leave children with IBD feeling 
socially isolated, triggering higher levels of anxiety and/or depression in both the child 
and his/her parents. Existing data suggest that patients with IBD are at higher risk of 
experiencing clinical anxiety and depression relative to their peers (McCombie, Mulder, 
and Gearry, 2015). Dealing with an array of physical and emotional changes makes 
adolescence a uniquely challenging part of childhood.  The added considerations that 
come with managing a chronic illness serve to increase the stress of an already stressful 
time, and thereby lower the overall quality of life for the child and their family. 
Parents of children with newly diagnosed IBD must reconcile themselves to the 
reality of their child’s chronic illness.  This can cause a high level of stress and manifest 
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as anxiety or depression (Jackson et al., 2015).  Parents may worry that something 
terrible might happen to their child, including death or hospitalization, and they may be 
unable to cope with the fear of an impending adverse event (Bishop, Lemberg, and Day, 
2014). In addition, parents may fear that they are not devoting enough time and energy to 
the other aspects of their life, such as work or their other children. These feelings can also 
lead to feelings of inadequacy, anxiety, and depression.  The ability of parents to cope 
with the diagnosis can also impact the ability of the child to cope so that coping in the 
parent-child dyad is inextricably connected (McCombie, Mulder, and Gearry, 2015). 
At present, insufficient prospective data is available investigating coping 
mechanisms and strategies of children and parents with a new diagnosis of IBD. 
Therefore, data from this study can help to identify patients and families who may benefit 
from additional psychosocial resources to enable them to better cope with IBD. 
Ultimately, the goal of the studies like this will be to gain data for use in promoting 













The main objective of this research is to assess if children with newly diagnosed 
IBD have a change in anxiety, depression, and/or quality of life during the first year of 
their diagnosis.  Additionally, we will measure changes in parental anxiety and/or 
depression over that first year.  We will assess for relevant clinical and environmental 
stressors. Ultimately, we hope to use these data to develop strategies that can mitigate 
stress and the subsequent incidence of mental illness after a child is given a diagnosis of 
IBD. To accomplish these goals, enrolled patients with newly diagnosed IBD complete 
validated surveys about how they feel and their disease state. Their parents also complete 
similar forms. 12-18 months later, parents and children complete the forms again, 
enabling the assessment of changes over time. We hypothesize that parental coping 
strategies will be related to those displayed by their children.  Furthermore, coping 
strategies will impact the incidence of anxiety, depression, and quality of life for both 








The Inflammatory Bowel Disease Coping Project at Boston Children’s Hospital is 
a longitudinal prospective study surveying coping mechanisms of parents and children 
with newly diagnosed with IBD. The goal of the study is to identify baseline and acquired 
factors contributing to the manifestation of less adaptive coping mechanisms.  These data 
will enable the future implementation of resources and techniques to reduce the burden of 
anxiety and depression in these children. We also hope to investigate way(s) in which 
parental coping affects a child’s coping. We hypothesize that the information that we gain 
from this study will permit the rational development of improved strategies to support 
families that are struggling to cope with a new diagnosis of IBD.  
Children and parents are asked to complete a series of validated questionnaires 
with a window of about six months from diagnosis.  Children and parents fill out similar 
forms 12-18 months later. There is no compensation for participation in this study, and 
the family may choose not to participate or to rescind consent at any time point. Children 
and their parents may choose to omit questions that they do not feel comfortable 
answering. Each patient is given an identification number to ensure confidentiality in 
each survey, and no protected health information (PHI) is included in any survey. If the 
responses of the administered questionnaires indicate that a patient is at risk of harming 
themselves or others, the research team will immediately alert the patient’s physician. 
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This study was approved by the Institutional Review Board at BCH (Protocol 
Number: P0023915) with Continuing Review approved on July 15, 2019, to extend the 
study to July 24, 2020. This study began on January 1, 2017, and the information in this 
thesis refers to data from that point until March 31, 2020. 
Enrollment in the Coping Study: 
 Members of the research team utilized electronic medical records to identify 
patients with newly diagnosed IBD. Also, potential study subjects were identified 
through a review of weekly GI pathology reports, the inpatient GI list, and the 
ambulatory IBD schedules at both BCH and its Waltham satellite. Inclusion criteria 
included patients between 9 and 17 years that were diagnosed with IBD within the last 
six months. In addition, patients must speak English as their first language and be treated 
at BCH for the duration of their time in the study. 
Before any patient was approached for participation in the study, their primary GI 
physician was contacted to see if the provider believed that the patient was eligible.  The 
patient must not have recently changed any psychotropic medications. Once permission 
was obtained from the provider, the research team would approach the patient and his/her 
family at an appointment, infusion, or their room if they were inpatient at the time. The 
member of the research team would then explain the purpose of the study and what 
participation would entail. If the patient and his/her family were interested in the study, 
the parent would complete the consent form (Figure 2), which would be dated and signed 
by the parent, the patient, and the Research Study Coordinator.  Once the patient and 
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parents had completed the questionnaires, the Research Study Coordinator double-
checked that the patient had answered every question and that no questions or pages had 
been overlooked. 
Eligible patients without an upcoming appointment were contacted via email. 
Once consented, these patients were given the option of completing the surveys online.  
Alternately, they also had the option to take home the surveys and mail them back to the 
hospital once completed. 
Questionnaires: 
 The measures utilized in this study were completed at baseline (new diagnosis) 
and then again 12-18 months later. The patient and their parents completed a total of 
seven survey metrics (see below). 
 The first five measures are given to the child for completion at both the baseline 
and follow-up appointments. 
1. The Impact III Questionnaire (Otley et al., 2002, 2006) (Figure 3) was designed 
specifically for use in children with IBD. The survey contains 35 questions, each 
with a four-point Leichert scale. The questionnaire assesses Health-Related 
Quality of Life (HRQOL) along six domains: Body Image, Treatments and 
Interventions, Bowel Symptoms, Social Functioning, Emotional Functioning, and 
Systemic Symptoms. The questions ask if the child is in any pain, as well as how 
they feel in general, about their diagnosis, and about their overall symptoms. 
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2. The Children’s Depression Inventory (CDI) (Kovacs, 1992) (Figure 4) is a 
questionnaire that contains 27 questions with a three-point Leichert scale.  The 
questions were designed to identify depression in children and adolescents, and 
the responses correspond to how the child felt over the last two weeks. The 
questions are divided along five dimensions: Negative Mood, Interpersonal 
Problems, Ineffectiveness, Anhedonia, and Negative Self-Esteem. The CDI scores 
range from 0-54 and are standardized to T-scores that are adjusted for the sex and 
age of the child. Scores along each of the five dimensions, discern children that 
may be more or less at risk for suffering from the symptoms of depression. 
3. The Screen for Child Anxiety Related Emotional Disorders (SCARED, Child 
Version) (Birmaher et al., 1999) (Figure 5) contains 41 questions that assess for 
anxiety in children and adolescents. The questions each ask about specific 
behaviors or feelings, and there are three possible answer choices: “Not true or 
hardly ever true,” Somewhat or sometimes true,” or “Very True or Often True.” 
These answers correspond to the numbers 0, 1, or 2. The survey utilizes the 
frequency of these feelings or behaviors to assess for potential anxiety disorders. 
4. The Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001) 
(Figure 6) that, like the CDI, screens for depression. There are 10 questions, 9 of 
which have a four-point Leichert scale. The questions ask about experiences that 
the patient has had or not had over the last two weeks, and the answer choices are 
“not at all,” “several days,” “more than half the days,” or “nearly every day,” 
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These answer choices correspond to the numbers 0, 1, 2, or 3. The final question 
asks if these experiences affect the patient’s ability to live a normal life.  
The final three measures are given to the parent or legal guardian of the child for 
completion at both the baseline and follow-up appointments. 
5. The Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) 
(Figure 7) is a survey with 14 questions, each with a four-point Leichert scale. 
The survey has seven questions about anxiety and seven questions about 
depression. The patient answers each question about how he/she has felt this last 
week.  
6. The Pediatric Inventory for Parents (PIP) (Streisand, Braniecki, Tercyak, & 
Kazak, 2001) is a survey given to parents of ill children to assess for parental 
stress (Figure 8). The questionnaire has 42 questions, each of which has two 
answer columns related to the frequency and difficulty of an event. The frequency 
column assesses how many times the given event has occurred over the last week, 
with answer choices “Never,” “Rarely,” “Sometimes,” “Often,” and “Very 
Often.” These choices correspond to numbers 0, 1, 2, 3, or 4. The difficulty 
column assesses how difficult the occurrence was for the parent, with answers 
“Not at all,” “A little,” “Somewhat,” “Very much,” and “Extremely,” also 
corresponding to the numbers 0, 1, 2, 3, or 4. Questions fall into four dimensions, 
including Communication, Emotional Distress, Medical Care, or Role Function. 
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7. The Healthcare Utilization Survey (HUS) (Figure 9) includes six questions that 
ask the parent how often in the last month the family had to take action involving 
the child’s IBD, including office visits, ER visits, hospitalizations, and phone 
calls with the physician. The parent can write in any number, including 0.  
Data Collection: 
 Data collected from patients enrolled in the study was input into both Microsoft 
Word and Microsoft Excel (Microsoft Corporation, Redmond, WA), which was locked 
into a server behind the digital firewall at BCH. Data from ineligible subjects was 
recorded to prevent reapproaching patients that didn’t meet inclusion criteria or 
previously declined participation. Information from each patient was found on 
PowerChart, the electronic medical record system used by BCH. Once enrolled in the 
study, questionnaires (Figures 3-8) were distributed to the patient and his/her parent, or 
they could choose to complete the metrics online.  Electronically submitted data was 
collected using Research Electronic Data Capture (REDCap), a commercially available, 
HIPPA-compliant data warehouse.  REDCap enables Research Study Coordinators to 
send an email to enrolled subjects, including a direct link to the surveys.  
 All enrolled patients were provided with a study ID number beginning with the 
letters BCOPE, and this unique and anonymous identifier was used in the subsequent 
analysis of all survey responses and clinical data to maintain confidentiality. Each 
subject’s data was stored in a separate online REDCap Case-Report Form (CRF). Each 
CRF included nine subsections that were completed by the Research Study Coordinator. 
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Data in these subsections were recorded in three sections, including baseline IBD 
measures and demographic data, enrollment and follow-up survey responses, and clinical 
outcome. 
 The baseline and follow-up IBD clinical outcome data were abstracted from  
PowerChart to identify potential correlates between disease severity and coping scores to 
create a narrative connecting the two. Baseline data included demographics, date of 
diagnosis, physician global assessment of disease activity, the severity of disease (as 
assessed by PCDAI and PUCAI), disease phenotype, and disease extent. Follow up data 
included a need for surgery, frequency of IBD flares, steroid usage, need for emergency 
department evaluation or hospitalization, IBD-related ambulatory appointments, and 
correspondence with GI providers. Clinical laboratory data collected included ESR, CRP, 
and HCT, and stool study biomarkers (lactoferrin and calprotectin). The names and 
dosing of IBD related medications were also recorded. 
 Data from completed surveys was inputted directly into REDCap.  Consent forms 
were both kept in a locked setting in the IBD Center, and all original materials were 








 A total of 75 patients were enrolled in the study and completed all questionnaires.  
As of 2/29/20, 15 of these enrolled subjects completed the study and provided follow-up 
survey and clinical data. There are still 40 patients remaining who have not yet reached 
the one year follow up (1YFU) date.  Seventeen subjects have been lost to follow-up.  
Twelve of these patients did not schedule follow-up clinical appointments and failed to 
respond to study email prompts.  Three of the remaining 5 patients were approached to 
complete follow up questionnaires but were no longer interested in the study. Three 
patients have reached their one-year follow-up date and will be approached at their next 
appointment. The enrolled patient population who completed questionnaires can be seen 
in the flowchart in Figure 1.  
There was a gender distribution in the study (Table 1), with 44 males (58.67%) 
and 31 females (41.33%). 48 of the patients had CD (63.16%), and 28 had UC (36.84%). 
The average age at enrollment was 14.68 years, making the average age at diagnosis 14 
years old. The range of ages at consent was 7.48. 
 There was a gap in the research in the summer of 2019, and 12 patients were 
initially lost to follow-up. However, the window for follow-up was subsequently 
extended to 12-18 months from enrollment to include as many patients as possible and 
particularly to include those patients who are not often at the hospital for appointments.  
Engaging patients at appointments proved to be the most successful way to approach 
them for participation or to complete follow-up paperwork. Some of the patients that 
were initially enrolled in the study failed to respond to questions on the surveys.  The 
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study protocol was modified to include a follow-up by Research Study Coordinators to 
ensure that all survey metrics had been answered. Enrolled subjects with missing data 
were excluded from data analysis. 
 





Total Consented - 75 
Baseline Data - 75 
Follow-up Data 
Yes - 15 No - 60 
Awaiting Follow-up 
- 43 





Table 1: Enrolled Patient Demographics 
Demographic Characteristic Classification Number Percent Range 
Gender Male 44 58.67% N/A 
 Female 31 41.33% N/A 
Age at Consent Mean 14.68 N/A 7.48 
Diagnosis CD 48 63.16% N/A 











 Patients were allowed to opt-out of any survey questions.  As such, different 
numbers of responses were available for different study questions. The average scores for 
each questionnaire were calculated (Table 2).  The healthcare utilization survey was 
excluded from this analysis since no score is calculated. Raw scores, as well as scoring 
ranges, are reported for each questionnaire.  
 Sixty-five out of 75 enrolled patients completed baseline Impact-III metrics, and 
the average scores are reported in Table 2. The average total score is 126.38, and the 
range of scores is from 35-175. Higher scores indicate a better quality of life. 
 Baseline Children’s Depression Inventory (CDI) data were available from 68 of 
75 total enrolled patients, and the average baseline scores are reported in Table 2.  Raw 
scores were calculated for the CDI total score, and the average of the 68 scores was 5.38. 
	
18 
The range of scores was from 0-54, with a higher score indicating a higher risk of 
depression and depressive symptoms. 
Baseline SCARED-child questionnaire data were available from 66 of 75 enrolled 
subjects, and the average baseline scores are reported in Table 2. Scores higher than 25 
indicate a risk for anxiety disorders. The average score on the SCARED measure was 
18.23, and 50.75% of the patients had a score greater than 25, indicating some form of 
anxiety. 
 The PHQ-9 average baseline scores are reported in Table 2. Sixty-three of 75 
enrolled patients completed the PHQ-9 form. The scores range from 0-27, with higher 
scores indicating a higher risk of depression. The average score was 4.19, which falls 
under the category of minimal depression. Thirty-two scored between 0-4 (minimal 
depression), 19 scored between 5-9 (indicating mild depression), and 9 scored between 
10-14 (moderate depression). No patients had scores indicative of moderately severe 
depression (15-19) or severe depression (20-27). 
 
Parent Results: 
 Average baseline scores for the Hospital Anxiety and Depression Inventory for 
both anxiety and depression are reported in Table 2. The scores range from 0-21, and 
there was a disparity noted between parents at risk of anxiety and depression. The 
average anxiety score is 6.99, while the average depression score is 3.95. Higher scores 
indicate a higher risk of anxiety or depression. 
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 The average baseline scores for frequency and difficulty on the PIP are reported 
in Table 2. Out of 75 total enrolled patients, 65 of their parents completed the PIP, with 
scores range from 42-210 (higher scores reflecting greater difficulty or frequency of 
adverse events relating to their child). The average score for frequency was 99.76, and 







Table 2: Baseline Results for IBD Coping Study Metrics 
 
 
Metric Score Category Mean Score Score Range 
Impact-III Total 126.38 35-175 
CDI Total 5.38 0-54 
HADS Anxiety 8.77 0-21 
  Depression 7.17 0-21 
SCARED  Total 23 Not Defined 
PIP Frequency 99.76 42-210 
  Difficulty 92.02 42-210 










Initial and follow-up average scores on all questionnaires, along with the 
difference between the two, is reported in Table 3. 
 
 
Table 3: Average baseline and follow-up scores on each metric, and the difference 
between the two. 
 
 





Difference in Initial 
and Follow-Up 
Score 
Impact-III Total 126.38 130 3.62 
CDI Total 5.38 5.03  0.35 
HADS Anxiety 8.77  4.77 4 
 Depression 7.17 3.58 3.583 
SCARED Total 23 21.08 1.92 
PIP Frequency 99.76 78.31 21.42 
 Difficulty 92.02 79.23 12.69 








 The SCARED questionnaire assesses a child is suffering from one of many forms 
of anxiety.  Baseline data were available for 66 of 75 patients, and 12 patients provided 
follow-up data after one year, The baseline average SCARED score was 23.0, with 
50.75% of patients showing anxiety.  Follow-up average SCARED scores fell to 21.08, 
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with 33.33% of reporting patients manifesting responses consistent with anxiety. This 
data can be seen in Figure 2. 
 
 
Figure 2: SCARED-child: This figure shows the mean initial and follow-up scores on 







 The PHQ-9 and the CDI both assess for childhood depression. The average 
baseline PHQ-9score for the 63 (of 75 enrolled) reporting patients was a 4.19. The 
average PHQ-9 score fell to 4.0 in 14 patients that completed the follow-up metric at one 
year. Initially, 32 patients (50.7%) scored between 0-4 (minimal depression), 19 patients 






















10-14 (moderate depression).  These data are illustrated in Figure 3. None of the patients 
scored between 15-19 (moderately severe depression) or 20-27 (severe depression). At 
the one-year follow-up, 10 (71.42%) had minimal depression, 2 (14.28%) had mild 
depression, and 2 (14.28%) had scores consistent with moderate depression. The average 
baseline CDI in 68 reporting was 5.37. The average CDI fell to 5.028 at the one- year 
follow-up (Figure 4). 
 
Figure 3: PHQ-9 data: This figure shows the percent of patients with PHQ-9 scores that 


































PHQ-9 Baseline   PHQ-9 Follow-up 
50.79% 
  30.16 % 
  14.29% 
  71.43 % 







Figure 4: CDI data: This graph shows the average initial and follow-up CDI scores. 






Child Quality of Life 
 
 Sixty-five out of 75 patients completed a baseline Impact-III questionnaire, which 
assesses the quality of life in children with chronic illnesses. The average score was 
126.38 at baseline, and it rose to 130 in 16 patients that completed the Impact-III form at 





























































Figure 5: Impact-III data: This graph shows the mean initial and follow-up IMPACT-





Parent Anxiety and Depression 
 
 Sixty-five out of 75 parents completed baseline HADS Surveys (Figure 6). To 
date, 12 parents have completed a follow-up survey. This survey was used to calculate 
anxiety and depression in parents of children with IBD.  The baseline average anxiety 
score was 8.77 and fell to 4.77 after one year.  The baseline and follow-up mean average 





Figure 6: HADS survey results for parents: This figure shows the initial and follow-up 
scores for parents on the HADS surveys for both anxiety and depression. Asterisk 





































 65 out of 75 parents completed baseline PIP questionnaires, which assess the 
frequency and difficulty of adverse events having to do with their child’s IBD diagnosis 
(Figure 7).  To date, 12 have completed follow-up questionnaires.  The baseline average 
frequency score was 99.75, and after one year, fell to 78.31.  Similarly, the mean 





Figure 7: PIP data parents: This graph shows the initial and follow-up mean scores on 
the PIP survey. Asterisk indicates significant difference (p < 0.05). Error bars show +/- 1 
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 The data collected in this study contribute further insight into the interplay 
between disease activity and psychosocial adaptation in children and parents with IBD.  
Previous studies have documented that the incidence of anxiety and depression is higher 
in chronically ill patients (Streisand et al., 2009), and particularly in those patients with 
IBD (Rosen, Dhawan, and Saeed, 2015, McCombie, Mulder, and Gearry, 2015).  
Interestingly, the average IMPACT-III scores presented in Table 2 was 126.38, indicating 
an above-average quality of life in these children. The average CDI score (5.37) reflects a 
low incidence of depression in our study population as well. However, these findings 
should be viewed in the context of the relatively small sample size and scoring range.    
The PHQ-9 scores permitted a more detailed analysis by being stratifying patient 
responses into discrete categories, including minimal, mild, moderate, moderately severe, 
and severe depression.  No patients in this study had PHQ-9 scores that placed them into 
anything more than moderate depression. Nonetheless, approximately 50% of the patients 
had PHQ-0 scores in either the mild or moderate depression range, which seems to be in 
concert with previous reports (McCombie, Mulder, and Gearry, 2015). 
SCARED scoring suggested that 50.75% of patients at baseline provided 
responses consistent with some type of anxiety disorder. The responses of these 
questionnaires are consistent with previous findings demonstrating that children with 
chronic illnesses, including those with IBD, are at a higher risk for anxiety and 
depression.  Therefore, it would be beneficial to surveil this at-risk population early in the 
course of their disease. 
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 The inclusion of parental survey data in this prospective cohort study provided 
additional insight into which adaptive (or maladaptive) coping strategies are prevalent in 
the home. The data in Table 2 indicate that the parents of children with IBD also suffer 
from anxiety and depression. In contrast, PIP scores, which assess the frequency and 
difficulty of stressful events, reflected relatively low levels of parental stress. These 
findings are similar to those reported by Streisand and Mackey (2009) in their assessment 
of coping in mothers of children with diabetes. 
 Data in Table 3 includes the change between average baseline and follow-up 
scores for each study metric. It is interesting to note that there was an overall trend in 
improvement in psychometric scores, including lower anxiety or depression in children or 
parents, higher quality of life, or lower levels of stress in parents.  These findings are 
important, as there is not a great deal of data on long-term coping mechanisms of patients 
with IBD. Each result will be discussed in more detail in the following sections. 
 There was a drop from 50% to 33% in the percentage of patients with longitudinal 
SCARED scores greater than 25 (Figure 2).  Though the overall trend reflects a fall in 
levels of anxiety one year from diagnosis, these differences were not statistically 
significant by T-test (p = 0.41). 
 Two of the questionnaires assessed depression: the PHQ-9 and the CDI.  The 
mean baseline and follow-up PHQ-9 scores are presented in Figure 3.  On the left can be 
seen baseline data, and on the right is the follow-up data.  At baseline, 50.79% of the 
patients had scores consistent with minimal depression, while the rest of the patients had 
either mild (30.16%) or moderate depression (14.29%).  The number of patients with 
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minimal depression increased to 71.43% at the one-year follow-up.  This trend may have 
been the result of a reclassification of patients from mild to minimal depression, as there 
was no significant change in the percentage of patients with moderate depression 
(14.23%). While the differences in scores were not statistically different (p = 0.381), 
there appears to be a trend toward decreased burden from more significant degrees of 
depression in this study population. 
The baseline and follow-up CDI scores are reported in Figure 4, with error bars 
representing +/- 1 standard deviation from the mean. While there was an overall fall in 
scores from 5.37 (in 68 subjects) to 5.03 (in 14 subjects), consistent with lower levels of 
depression after one year, the scores were not statistically distinguishable.  
Baseline and follow-up IMPACT-III scores are reported in Figure 5.  There was 
an insignificant improvement from 126.38 (in 65 subjects) vs. 130 (in 16 subjects), in 
average baseline and follow-up scores, respectfully (p = 0.37).  This trend is consistent 
with previous literature on quality of life measures in children with IBD (Werner et al., 
2014). 
 The data from this study is consistent with previous research on the topic. 
However, there is very little prospective longitudinal data relating to the effects of coping 
in patients with IBD, especially for children (Mackner and Crandall, 2005). The parents 
of children with newly diagnosed IBD experienced a more significant change in their 
anxiety and depression scores when compared to their children.  This suggests that there 
may be a greater need to develop effective interventions to better support parents during 
this especially difficult time.  Nonetheless, even in the absence of therapeutic 
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interventions, HADS scoring (Figure 6) demonstrated a significant decrease in anxiety (p 
= 0.03) and depression scores (p = 0.02) in these parents during the first year after their 
child’s diagnosis with IBD. 
 The data from PIP questionnaires assessing the frequency and difficulty of 
stressful events in these parent’s lives related to their child’s IBD are presented in Figure 
7.  While there was a significant decrease in the frequency of adverse events after the first 
year (p = 0.02), there was no parallel decrease in the difficulty of these events (p = 0.26).  
However, the trend was quite positive, as the reported difficulty of these events decreased 
from 92.02 to 79.23.  
 The main difficulty in interpreting these data is derived from the potential for 
sampling error. We have a small patient population, particularly concerning follow-up.  
Therefore, we continue to collect these data to enable a more robust analysis in 6-12 
months.   
 There are limitations to this study and its design. The initial cohort of patients 
completed only some of the questionnaires, and we have since corrected this by ensuring 
that patients and their families have had the opportunity to complete all of the questions 
in each of the surveys to the best of their knowledge and level of comfort.  We found that 
approaching patients during a clinic appointment, in their inpatient hospital room, or 
during a regularly scheduled infusion, was the best way to gain consent for the project 
and have them fill out the forms.  Emailing patients and having them complete surveys 
online or at home was more efficient, but generally less productive.  
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 Future studies will further address age differences in the responses to the surveys. 
In our study population, younger patients (aged 9-12) appeared to report better quality of 
life, as well as less anxiety and depression than older teenage patients (aged 13-17).  This 
difference could be attributed to sampling or reporting bias, or the different way(s) in 
which children and adolescents view the impact of their disease. As such, supportive 
interventions targeting teens may be especially relevant.  Additionally, it would be useful 
to stratify the analysis to control for patients with previous diagnoses of anxiety or 
depression, since their subjective experience may skew the results.  
 Parental data collected in the Healthcare Utilization Surveys were not included in 
this analysis due to the lack of standardization, as well as the inclusion of open-ended 
responses.  Future research will utilize the responses from these surveys to correlate 
degrees of anxiety and depression with the level of healthcare utilization. 
 Future studies will correlate the degree of anxiety, depression, and quality of life 
in children, as well as anxiety, depression, and stress in parents, with clinical disease 
severity.  Stratified analysis of a larger dataset would be useful to assess differences in 
responses provided by patients with Crohn’s disease and those with ulcerative colitis. 
Data from this study, as well as other studies, will contribute to the development of 
evidence-based psychosocial interventions in this vulnerable population.  Whenever 
possible, these interventions should take into account particulars, including age, 
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Figure 9. The BCH IBD Coping Project Research Consent Form. 	
This section only to be edited by IRB office.
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Please check one of the following:
_____ You are an adult participant in this study.
_____ You are the parent or guardian granting permission for a child in this study.
 
If the participant is a child the use of "you" refers to "your child" 
This consent form gives you important information about a research study.  A research study helps scientists 
and doctors learn new information to improve medical practice and patient care.
Participation in this research study is voluntary. You are free to say yes or no and your decision will not impact 
the care you receive at Boston Children’s Hospital. You can withdraw from the study at any time.  A 
description of the study and its risks, potential benefits and other important information are in this consent form.  
Please read this consent form carefully and take your time making a decision. The form may contain words that 
you do not understand. Please ask questions about anything you do not understand. We encourage you to talk to 
others (for example, your friends, family, or other doctors) before you decide to participate in this research 
study.   
How are individuals selected for this research study?
You are being asked to participate in this research study because you were recently diagnosed with 
Inflammatory Bowel Disease (IBD) and are a patient at Boston Children's Hospital.
Why is this research study being conducted?
In this research study we want to learn more about how families cope with a new diagnosis of Inflammatory 
Bowel Disease (IBD).  We believe that if we have a better understanding of how families cope with IBD, we 
can develop better ways to support them in the future.
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Who is conducting this research study, and where is it being conducted?
This research study is being conducted by Drs. Zimmerman, Rufo, Bujoreanu and their associates at Boston 
Children’s Hospital.  Dr. Zimmerman will be the primary person conducting the study.
Your health care provider may be a research investigator for this research and as an investigator, is interested in 
both your clinical welfare and in the conduct of this study.  Before entering this study or at any time during the 
research, you may ask for a second opinion about your care from another health care provider who is in no way 
associated with this project. You are not under any obligation to participate in any research project offered by 
your health care provider. If you choose not to participate or not to allow your child to participate, your care at 
Boston Children’s Hospital and/or with your health care provider will not be affected in any way at all.
How many people will participate in this research study?
We plan on enrolling 50 IBD patients and families from Boston Children's Hospital in this study.
What do I have to do if I am in this research study?
You will participate in this study around the time of your diagnosis.  Additionally, we will be asking you to 
provide answer the same questionnaires during a follow-up visit about 12 months later.  This follow-up visit 
will occur during a scheduled clinic appointment, medically indicated procedure, or medication infusion. 
Alternatively, it may include returning the questionnaires to the study team via mail.
If you agree to participate in this study, you will be asked to fill out various questionnaires about psychological 
functioning and other questions about medical care.  Completion of these questionnaires should take about 10-
20 minutes. The information in these questionnaires will not become part of your medical record.  Each 
questionnaire will be coded by number, and will not contain any personally identifiable information. You 
medical record will be reviewed by the research personnel to obtain information about your diagnosis and 
medical care.
What are the risks of this research study? What could go wrong?
You may be asked questions that make you uncomfortable or cause you to remember situations that were 
upsetting to you.  You may become frustrated if you are asked questions during the (survey/interview) that you 
do not know how to answer.  You may not be able to answer all the questions and you do not need to answer 
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any questions that you do not wish to answer.  If you become upset at any time, you can stop the 
(survey/interview).  We will also offer to have you speak to someone about how you are feeling.   
If, during your participation in this research, there is reason to believe that you or your child are at risk for being 
suicidal or otherwise harming yourself, (or risk of harming others) the research team is required by law and 
Hospital policy to act on this suspicion.  This may include notifying your parent(s), your therapist(s) if 
applicable, or other individuals.  If this were to occur, we would not be able to assure confidentiality, but we 
would let you know that we plan to disclose this information because we felt it best for your safety (or the 
safety of others).
You may withdraw from the research study at any time with no consequences. If you choose to no longer 
participate in the study before data is gathered, notify a nurse, GI physician, or study personnel.
What are the benefits of this research?
Being in this research may not help you right now.  When we finish the research, we hope that we will know 
more about how children and families cope with chronic gastrointestinal illness.  This understanding will help 
us to develop therapies and programs aimed at supporting families with a child with a new chronic diagnosis 
such as IBD. Some children and adolescents and their parents appreciate having this opportunity to contribute to 
this effort to better understand and support patients and families like themselves who are learning to cope with a 
new diagnosis of ulcerative colitis or Crohn disease.
Are there costs associated with this research? Will I receive any payments?
Participation in this study is voluntary. There is no compensation associated with this study. 
If I do not want to take part in this research, what are the other choices?
Participation in this study is voluntary. Since the study does not include any medical therapy or surgical 
intervention, no alternative to the study exists. Your medical care at Children’s Hospital Boston will not be 
affected if you do not choose to participate in this study.
 
Are there other things I should know about?
If we find out about new information from this research or other research that may affect your health, safety or 
willingness to stay in this research we will let you know as soon as possible.
Protocol ID:IRB-P00023915                 Activation Date:   July   25, 2019                 Do Not Use After:   July   24, 2020
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Why would I be taken off the study early?
The research investigator may take you out of this study at any time. This would happen if:
• The research is stopped. 
• You are not able to attend the research visits required.
• You fail to follow the research requirements.
• You need a treatment or medication that may not be taken while on the research or the research 
investigator feels it is in your best interest to be taken out of this research.
If this happens, the research investigator will tell you.
Other information that may help you:
Boston Children’s Hospital has developed a web-based, interactive educational program for parents called “A 
Parent’s Guide to Medical Research.”  To find out more about research at Children’s, please visit the program at 
www.researchchildren.org. 
Boston Children’s Hospital is interested in hearing your comments, answering your questions, and responding 
to any concerns regarding clinical research. If you have questions or concerns, you may email 
IRB@childrens.harvard.edu or call (617) 355-7052 between the hours of 8:30 and 5:00, Monday through 
Friday.
Who may see, use or share your health information? 
A copy of this consent form will not be placed in your medical record. 
The results of the tests performed for research purposes will not be placed in your medical record. Because of 
this, it is unlikely that others within the hospital, an insurance company, or employer would ever learn of such 
results.
Contact for Future Studies: Your participation in any research is completely voluntary and you should feel no 
pressure to participate if you are contacted about another research study.
Please check and initial one of the options below regarding future contact about other research done by us or 
other researchers we are working with (collaborators). 
_______  Yes, I may be contacted about participating in other research projects studying Inflammatory 
Bowel disease or related conditions. I give permission for my contact information (name and 
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mailing address and/or phone number) to be given to other researchers working with the study 
investigator at Boston Children’s Hospital.
_______ No, I do not want to be contacted about other research projects. Do not give my contact 
information to the staff of any other research studies.
What should you know about HIPAA and confidentiality?
Your health information is protected by a law called the Health Information Portability and Accountability act 
(HIPAA). In general, anyone who is involved in this research, including those funding and regulating the study, 
may see the data, including information about you.  For example, the following people might see information 
about you:
• Research staff at Boston Children’s Hospital involved in this study; 
• Medical staff at Boston Children’s Hospital directly involved in your care that is related to the research 
or arises from it;
• Other researchers and centers that are a part of this study, including people who oversee research at that 
hospital;
• People at Boston Children’s Hospital who oversee, advise, and evaluate research and care. This includes 
the ethics board and quality improvement program;
• People from agencies and organizations that provide accreditation and oversight of research;
• People that oversee the study information, such as data safety monitoring boards, clinical research 
organizations, data coordinating centers, and others;
• Sponsors or others who fund the research, including the government or private sponsors.
• Companies that manufacture drugs or devices used in this research;
• Federal and state agencies that oversee or review research information, such as the Food and Drug 
Administration, the Department of Health and Human Services, the National Institutes of Health, and 
public health and safety authorities;
• People or groups that are hired to provide services related to this research or research at Boston 
Children’s Hospital, including services providers, such as laboratories and others;
• And/or your health insurer, for portions of the research and related care that are considered billable.
If some law or court requires us to share the information, we would have to follow that law or final ruling.
Some people or groups who get your health information might not have to follow the same privacy rules. Once 
your information is shared outside of Boston Children’s Hospital, we cannot promise that it will remain private. 
If you decide to share private information with anyone not involved in the study, the federal law designed to 
protect privacy may no longer apply to this information. Other laws may or may not protect sharing of private 
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health information. If you have a question about this, you may contact the Boston Children’s Hospital Privacy 
Officer at (857) 218-4680, which is set up to help you understand privacy and confidentiality.
Because research is ongoing, we cannot give you an exact time when we will destroy this information.  
Researchers continue to use data for many years, so it is not possible to know when they will be done.
We will also create a code for the research information we collect about you so identifying information will not 
remain with the data and will be kept separately. The results of this research may be published in a medical 
book or journal or be used for teaching purposes.  However, your name or identifying information will not be 
used without your specific permission. 
Your privacy rights
If you want to participate in this research study, you must sign this form.  If you do not sign this form, it will not 
affect your care at Boston Children’s Hospital now or in the future and there will be no penalty or loss of 
benefits.  You can withdraw from the study and end your permission for Boston Children’s Hospital to use or 
share the protected information that was collected as part of the research; however you cannot get back 
information that was already shared with others. Once you remove your permission, no more private health 
information will be collected. If you wish to withdraw your health information, please contact the research 
team.
You may have the right to find out if information collected for this study was shared with others for research, 
treatment or payment. You may not be allowed to review the information, including information recorded in 
your medical record, until after the study is completed.  When the study is over, you will have the right to 
access the information again.  To request the information, please contact the Hospital’s Privacy Officer at (857) 
218-4680.
Contact Information
I understand that I may use the following contact information to reach the appropriate person/office to address 
any questions or concerns I may have about this study.  I know:






General questions about the study
 Research-related injuries or emergencies







General questions about the study
 Research-related injuries or emergencies
 Any research-related concerns or complaints
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Research  Contact: 
Sara Rogerson Phone: 617-919-4609  General questions about the study
 Research-related injuries or emergencies
 Any research-related concerns or complaints
Institutional Review 
Board 
Phone: 617-355-7052  Rights of a research participant 
 Use of protected health information.
 Compensation in event of research-related 
injury
 Any research-related concerns or complaints.
 If investigator/research contact cannot be 
reached.
 If I want to speak with someone other than the 
Investigator, Research Contact or research staff.
Documentation of Informed Consent and Authorization
 I have read this consent form and was given enough time to consider the decision to participate in this 
research.
 This research has been satisfactorily explained to me, including possible risks and benefits.
 All my questions were satisfactorily answered. 
 I understand that participation in this research is voluntary and that I can withdraw at any time.
 I am signing this consent form prior to participation in any research activities.
 I give permission for participation in this research and for the use of associated protected health 
information as described above (HIPAA). 
Parent/Legal Guardian Permission (if applicable) 
If the child to be involved in this research is a foster child or a ward of the state please notify the 
researcher or their staff who is obtaining your consent.
  __________________ ____________________________________________ _________________ 
  Date (MM/DD/YEAR) Signature of Parent #1 or Legal Guardian Relationship to child
Child Assent 
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__________________ ____________________________________________
   Date (MM/DD/YEAR) Signature of Child/Adolescent Participant
 If child/adolescent’s assent is not documented above, please indicate reason below (check one):
 Assent is documented on a separate IRB-approved assent form
 Child is too young
 Other reason (e.g. sedated), please specify: ____________________________________________
Research Investigator /or Associate’s Statement & Signature
 I have fully explained the research escribed above, including the possible risks and benefits, to all involved 
parties (participant /parents/legal guardian as applicable). 
 I have answered and will answer all questions to the best of my ability. 
 I will inform all involved parties of any changes (if applicable) to the research procedures or the risks and 
benefits during or after the course of the research. 
 I have provided a copy of the consent form signed by the participant / parent / guardian and a copy of the 
hospital’s privacy notification (if requested).
 __________________ ____________________________________________
   Date (MM/DD/YEAR) Signature of Research Investigator or Associate
Witness Statement & Signature
A witness must be present for the entire consent process in the following situations (please check the appropriate 
box) 
 The individual cannot read and this consent document was read to the participant or legal representative, or
 The individual has certain communication impairments that limit the participant’s ability to clearly express 
consent or 
 Situations where the IRB requests a witness be present: please specify _____________________
 I confirm that the information in this consent form was accurately explained to the participant, parent or legally 
authorized representative, the individual appeared to understand the information and had the opportunity to ask 
questions, and that informed consent was given freely.
    __________________          ____________________________________________             
        Date (MM/DD/YEAR)              Signature of Witness
Protocol ID:IRB-P00023915                 Activation Date:   July   25, 2019                 Do Not Use After:   July   24, 2020
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Or   
The individual is not English speaking and, through an interpreter, a short form consent document was 
presented orally to the participant or legal representative and this consent document serves as the summary for 
such consent.  
I confirm that the information in this consent form was presented orally to the participant, parent or legally 
authorized representative, in a language they could understand and the individual had the opportunity to ask 
questions.
    __________________          ____________________________________________             
        Date (MM/DD/YEAR)              Signature of Witness 
























































































































































































































































































































































































































Figure 12: Screen for Child Anxiety Related Emotional Disorders (SCARED). From 
(Birmaher et al. 1999).	
	
Screen for Child Anxiety Related Disorders (SCARED) 







Below is a list of sentences that describe how people feel. Read each phrase and decide if it is “Not True or Hardly 
Ever True” or “Somewhat True or Sometimes True” or “Very True or Often True” for you. Then for each sentence, 
fill in one circle that corresponds to the response that seems to describe you for the last 3 months.  
 
 0 














1. When I feel frightened, it is hard to breathe.    
2. I get headaches when I am at school.    
3. I don’t like to be with people I don’t know well.    
4. I get scared if I sleep away from home.    
5. I worry about other people liking me.    
6. When I get frightened, I feel like passing out.    
7. I am nervous.    
8. I follow my mother or father wherever they go.    
9. People tell me that I look nervous.    
10. I feel nervous with people I don’t know well.    
11. I get stomachaches at school.    
12. When I get frightened, I feel like I am going crazy.    
13. I worry about sleeping alone.    
14. I worry about being as good as other kids.    
15. When I get frightened, I feel like things are not real.    
16. I have nightmares about something bad happening to my 
parents. 
   
17. I worry about going to school.    
18. When I get frightened, my heart beats fast.    
19. I get shaky.    





Figure 12: Screen for Child Anxiety Related Emotional Disorders (SCARED). From 
(Birmaher et al. 1999).	(continued)	
Screen for Child Anxiety Related Disorders (SCARED) 
Child Version—Pg. 2 of 2 (To be filled out by the CHILD) 
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21. I worry about things working out for me.    
22. When I get frightened, I sweat a lot.    
23. I am a worrier.    
24. I get really frightened for no reason at all.     
25. I am afraid to be alone in the house.    
26. It is hard for me to talk with people I don’t know well.     
27. When I get frightened, I feel like I am choking.    
28. People tell me that I worry too much.    
29. I don’t like to be away from my family.    
30. I am afraid of having anxiety (or panic) attacks.    
31. I worry that something bad might happen to my parents.    
32. I feel shy with people I don’t know well.     
33. I worry about what is going to happen in the future.    
34. When I get frightened, I feel like throwing up.    
35. I worry about how well I do things.    
36. I am scared to go to school.    
37. I worry about things that have already happened.    
38. When I get frightened, I feel dizzy.    
39. I feel nervous when I am with other children or adults and I 
have to do something while they watch me (for example: read 
aloud, speak, play a game, play a sport.) 
   
40. I feel nervous when I am going to parties, dances, or any place 
where there will be people that I don’t know well. 
   
41. I am shy.    
 
SCORING: 
A total score of ≥ 25 may indicate the presence of an Anxiety Disorder. Scores higher that 30 are more specific. 
A score of 7 for items 1, 6, 9, 12, 15, 18, 19, 22, 24, 27, 30, 34, 38 may indicate Panic Disorder or Significant 
Somatic Symptoms. 
A score of 9 for items 5, 7, 14, 21, 23, 28, 33, 35, 37 may indicate Generalized Anxiety Disorder. 
A score of 5 for items 4, 8, 13, 16, 20, 25, 29, 31 may indicate Separation Anxiety Disorder. 
A score of 8 for items 3, 10, 26, 32, 39, 40, 41 may indicate Social Anxiety Disorder. 
A score of 3 for items 2, 11, 17, 36 may indicate Significant School Avoidance. 
*For children ages 8 to 11, it is recommended that the clinician explain all questions, or have the child answer the 
questionnaire sitting with an adult in case they have any questions. 
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Figure 13: Patient Health Questionnaire-9 (PHQ-9). From (Kroenke, Spitzer, and 
Williams, 2001). 
	
P A T I E N T  H E A L T H  Q U E S T I O N N A I R E - 9   
( P H Q - 9 )  
Over the last 2 weeks, how often have you been bothered 
by any of the following problems? 









1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3. Trouble falling or staying asleep, or sleeping too much 0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down 0 1 2 3 
7. Trouble concentrating on things, such as reading the 
newspaper or watching television 0 1 2 3 
8. Moving or speaking so slowly that other people could have 
noticed?  Or the opposite — being so fidgety or restless 
that you have been moving around a lot more than usual 
0 1 2 3 
9. Thoughts that you would be better off dead or of hurting 
yourself in some way 0 1 2 3 
                                                                                                              FOR OFFICE CODING     0      + ______  +  ______  +  ______ 
=Total Score:  ______ 
 
     
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 





















Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from 
Pfizer Inc.  No permission required to reproduce, translate, display or distribute. 
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